Droperidol

From Wikipedia, the free encyclopedia

Template:Short description Script error: No such module "Distinguish". Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Droperidol
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
PronunciationScript error: No such module "IPA".
Pregnancy
category		Page Template:Plainlist/styles.css has no content.
  • AU: C
Routes of
administration		Intravenous, Intramuscular
Drug classTypical antipsychotic
ATC codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Pharmacokinetic data
MetabolismHepatic
Elimination half-life2.3 hours
Identifiers
  • 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC22H22FN3O2
Molar mass379.435 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • c1ccc2c(c1)nc(n2C3=CCN(CC3)CCCC(=O)c4ccc(cc4)F)O

  • Fc1ccc(cc1)C(=O)CCCN2CC=C(CC2)N3c4ccccc4NC3=O
  • InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
  • Key:RMEDXOLNCUSCGS-UHFFFAOYSA-N
Data page
Template:Infobox drug/data page link

Droperidol /droʊˈpɛrɪdɔːl/ (Inapsine, Droleptan, Dridol, Xomolix, Innovar [combination with fentanyl]) is an antidopaminergic drug used as an antiemetic (that is, to prevent or treat nausea) and as an antipsychotic. Droperidol is also often used as a rapid sedative in intensive-care treatment, and where "agitation aggression or violent behavior"[3] are present.[4][5]

History

Discovered at Janssen Pharmaceutica in 1961, droperidol is a butyrophenone which acts as a potent D2 (dopamine receptor) antagonist with some histamine and serotonin antagonist activity.[6]

Medical use

It has a central antiemetic action and effectively prevents postoperative nausea and vomiting in adults using doses as low as 0.625 mg.

For treatment of nausea and vomiting, droperidol and ondansetron are equally effective; droperidol is more effective than metoclopramide.[7] It has also been used as an antipsychotic in doses ranging from 5 to 10 mg given as an intramuscular injection, generally in cases of severe agitation in a psychotic patient who is refusing oral medication. Its use in intramuscular sedation has been replaced by intramuscular preparations of haloperidol and olanzapine. Some practitioners recommend the use of 0.5 mg to 1 mg intravenously for the treatment of vertigo in an otherwise healthy elderly patients who have not responded to Epley maneuvers.

Black box warning

In 2001, the FDA changed the labeling requirements for droperidol injection to include a Black Box Warning, citing concerns of QT prolongation and torsades de pointes. The evidence for this is disputed, with 9 reported cases of torsades in 30 years and all of those having received doses in excess of 5 mg.[8] QT prolongation is a dose-related effect,[9] and it appears that droperidol is not a significant risk in low doses. A study in 2015 showed that droperidol is relatively safe and effective for the management of violent and aggressive adult[10] patients in hospital emergency departments in doses of 10mg and above and that there was no increased risk of QT prolongation and torsades de pointes.

Side effects

Dysphoria, sedation, hypotension resulting from peripheral alpha adrenoceptor blockade, prolongation of QT interval which can lead to torsades de pointes, and extrapyramidal side effects such as dystonic reactions/neuroleptic malignant syndrome.[11]

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content."Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
  2. ^ Page Module:Citation/CS1/styles.css has no content.Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in português do Brasil). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  3. ^ Edge R, Argáez C. Droperidol for Agitation in Acute Care [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK571530/
  4. ^ Page Module:Citation/CS1/styles.css has no content.Perkins J, Ho JD, Vilke GM, DeMers G (July 2015). "American Academy of Emergency Medicine Position Statement: Safety of Droperidol Use in the Emergency Department". The Journal of Emergency Medicine. 49 (1): 91–97. doi:10.1016/j.jemermed.2014.12.024. PMID 25837231.
  5. ^ Page Module:Citation/CS1/styles.css has no content.Klein LR, Driver BE, Horton G, Scharber S, Martel ML, Cole JB (May 2019). "Rescue Sedation When Treating Acute Agitation in the Emergency Department With Intramuscular Antipsychotics". The Journal of Emergency Medicine. 56 (5): 484–490. doi:10.1016/j.jemermed.2018.12.036. PMID 30745194. S2CID 73436531.
  6. ^ Page Module:Citation/CS1/styles.css has no content.Peroutka SJ, Synder SH (December 1980). "Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency". The American Journal of Psychiatry. 137 (12): 1518–1522. doi:10.1176/ajp.137.12.1518. PMID 6108081.
  7. ^ Page Module:Citation/CS1/styles.css has no content.Domino KB, Anderson EA, Polissar NL, Posner KL (June 1999). "Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis". Anesthesia and Analgesia. 88 (6): 1370–1379. doi:10.1213/00000539-199906000-00032. PMID 10357347.
  8. ^ Page Module:Citation/CS1/styles.css has no content.Kao LW, Kirk MA, Evers SJ, Rosenfeld SH (April 2003). "Droperidol, QT prolongation, and sudden death: what is the evidence?". Annals of Emergency Medicine. 41 (4): 546–558. doi:10.1067/mem.2003.110. PMID 12658255.
  9. ^ Page Module:Citation/CS1/styles.css has no content.Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J (November 1994). "Droperidol causes a dose-dependent prolongation of the QT interval". Anesthesia and Analgesia. 79 (5): 983–986. doi:10.1213/00000539-199411000-00028. PMID 7978420.
  10. ^ Page Module:Citation/CS1/styles.css has no content.Calver L, Page CB, Downes MA, Chan B, Kinnear F, Wheatley L, et al. (September 2015). "The Safety and Effectiveness of Droperidol for Sedation of Acute Behavioral Disturbance in the Emergency Department". Annals of Emergency Medicine. 66 (3): 230–238.e1. doi:10.1016/j.annemergmed.2015.03.016. PMID 25890395.
  11. ^ Page Module:Citation/CS1/styles.css has no content.Park CK, Choi HY, Oh IY, Kim MS (October 2002). "Acute dystonia by droperidol during intravenous patient-controlled analgesia in young patients". Journal of Korean Medical Science. 17 (5): 715–717. doi:10.3346/jkms.2002.17.5.715. PMC 3054934. PMID 12378031.

Further reading

Page Template:Refbegin/styles.css has no content.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Muscarinic acetylcholine receptor modulators Template:Nicotinic acetylcholine receptor modulators Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Retrieved from "https://cosmopedia.co/index.php?title=Droperidol&oldid=1703461"